Year-End Report July 2012 – June 2013

Eurocine Vaccines ends collaboration with Japanese company  Immunose™ FLU is repositioned for children, the segment of the influenza vaccines market that is projected to have the highest growth rate  New patent applications can give protection until 2032  Net loss for the financial year was SEK -13.0 million (p.y. -13.4 million)  Net loss for the last

Read More

Do you want to follow Eurocine Vaccines development?

Share our ambition developing more effective vaccines. Fill in your e-mail address and we will update you with the latest Press Releases and Stories.

Start your subscription here »